A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

Status unconfirmed

Conditions studied: Cancer

In brief

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

Key facts

Study ID

NCT04571398

Run by

Apricity Health, Inc

People needed

100

Starts

2019-11-19

Expected to finish

2023-10-15

Last updated by the study team

2020-10-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed cancer diagnosis
• Prescribed treatment with immune-checkpoint inhibitor
• Age ≥ 18 years
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• Uncomfortable with or unwilling to use digital or mobile technology
• Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow
• Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.

Where it is running

• Columbia University Irving Medical Center — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.